Meet Matthew, an osteosarcoma survivor, and learn how Voraxaze was a pivotal part of his successful fight against osteosarcoma. ➔

Meet Matthew, an osteosarcoma survivor, who received Voraxaze. ➔

This site is intended for US Healthcare Professionals Only

USA Flag
Prescribing Information
Important Safety Information
Placeholder

Terms of Use

rectangle-white-left-angle

This website (the “Website”) is owned by SERB Pharmaceuticals ("SERB") and is operated by SERB and its selected technology partners, which have agreed to comply with the SERB privacy policy posted on the Website (the “Privacy Policy”). Please be sure to read this Privacy Policy before using or submitting information to this Website. This site is governed solely by applicable federal and state laws and governmental regulations in the United States. Use of this Website constitutes your consent to application of such laws and regulations and to the terms of our Privacy Policy. Whenever you submit information via this Website, you consent to the collection, use, and disclosure of that information in accordance with this Privacy Policy. Your use of this Website is subject to our Legal Notice and Terms of Use.

To Order Voraxaze® Now, Call 1-855-786-7292
Indication and Important Safety Information
Indication and Limitations of Use
  • Voraxaze® is a carboxypeptidase indicated to reduce toxic plasma methotrexate concentration (greater than 1 micromole per liter) in adult and pediatric patients with delayed methotrexate clearance (plasma methotrexate concentrations greater than 2 standard deviations of the mean methotrexate excretion curve specific for the dose of methotrexate administered) due to impaired renal function
  • Limitations of Use: Voraxaze® is not recommended for use in patients who exhibit the expected clearance and expected plasma methotrexate concentration. Reducing plasma methotrexate concentration in these patients may result in subtherapeutic exposure to methotrexate
Important Safety Information
WARNINGS AND PRECAUTIONS

Serious Hypersensitivity Reactions

  • Serious hypersensitivity reactions, including anaphylactic reactions, may occur. Serious hypersensitivity reactions occurred in less than 1% of patients

Monitoring Methotrexate Concentration/Interference with Assay

  • Methotrexate concentrations within 48 hours following Voraxaze® administration can only be reliably measured by a chromatographic method due to interference from metabolites. Measurement of methotrexate concentrations within 48 hours of Voraxaze® administration using immunoassays results in an overestimation of the methotrexate concentration

ADVERSE REACTIONS

  • In clinical trials, the most common related adverse events (occurring in >1% of patients) were paresthesia, flushing, nausea and/or vomiting, hypotension and headache

DRUG INTERACTIONS

  • Voraxaze® can decrease leucovorin concentration, which may decrease the effect of leucovorin rescue unless leucovorin is dosed as recommended, and may also reduce the concentrations other folate analogs or folate analog metabolic inhibitors

Please see full Prescribing Information.